TY - JOUR
T1 - Timing of antiretroviral therapy for HIV in the setting of TB treatment
AU - Karakousis, Petros C.
AU - Piggott, Damani A.
PY - 2011
Y1 - 2011
N2 - The convergent human immunodeficiency virus (HIV) and tuberculosis (TB) pandemics continue to collectively exact significant morbidity and mortality worldwide. Highly active antiretroviral therapy (HAART) has been a critical component in combating the scourge of these two conditions as both a preemptive and therapeutic modality. However, concomitant administration of antiretroviral and antituberculous therapies poses significant challenges, including cumulative drug toxicities, drug-drug interactions, high pill burden, and the immune reconstitution inflammatory syndrome (IRIS), thus complicating the management of coinfected individuals. This paper will review data from recent studies regarding the optimal timing of HAART initiation relative to TB treatment, with the ultimate goal of improving coinfection-related morbidity and mortality while mitigating toxicity resulting from concurrent treatment of both infections.
AB - The convergent human immunodeficiency virus (HIV) and tuberculosis (TB) pandemics continue to collectively exact significant morbidity and mortality worldwide. Highly active antiretroviral therapy (HAART) has been a critical component in combating the scourge of these two conditions as both a preemptive and therapeutic modality. However, concomitant administration of antiretroviral and antituberculous therapies poses significant challenges, including cumulative drug toxicities, drug-drug interactions, high pill burden, and the immune reconstitution inflammatory syndrome (IRIS), thus complicating the management of coinfected individuals. This paper will review data from recent studies regarding the optimal timing of HAART initiation relative to TB treatment, with the ultimate goal of improving coinfection-related morbidity and mortality while mitigating toxicity resulting from concurrent treatment of both infections.
UR - http://www.scopus.com/inward/record.url?scp=79952222721&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952222721&partnerID=8YFLogxK
U2 - 10.1155/2011/103917
DO - 10.1155/2011/103917
M3 - Review article
C2 - 21234380
AN - SCOPUS:79952222721
SN - 1740-2522
VL - 2011
JO - Clinical and Developmental Immunology
JF - Clinical and Developmental Immunology
M1 - 103917
ER -